Rosuvastatin alters the genetic composition of the human gut microbiome
Authors:
Open Access
- 25 March 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Abstract
The gut microbiome contributes to the variation of blood lipid levels, and secondary bile acids are associated with the effect of statins. Yet, our knowledge of how statins, one of our most common drug groups, affect the human microbiome is scarce. We aimed to characterize the effect of rosuvastatin on gut microbiome composition and inferred genetic content in stool samples from a randomized controlled trial (n = 66). No taxa were significantly altered by rosuvastatin during the study. However, rosuvastatin-treated participants showed a reduction in the collective genetic potential to transport and metabolize precursors of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO, p < 0.01), and an increase of related metabolites betaine and γ-butyrobetaine in plasma (p < 0.01). Exploratory analyses in the rosuvastatin group showed that participants with the least favorable treatment response (defined as < median change in high-density/low-density lipoprotein (HDL/LDL) ratio) showed a marked increase in TMAO-levels compared to those with a more favorable response (p < 0.05). Our data suggest that while rosuvastatin has a limited effect on gut microbiome composition, it could exert broader collective effects on the microbiome relevant to their function, providing a rationale for further studies of the influence of statins on the gut microbiome.Keywords
Funding Information
- Helse Sør-Øst RHF (2016067)
- Norges Forskningsråd (240787/F20)
This publication has 41 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Statin use and the risk of Clostridium difficile in academic medical centresGut, 2012
- Enteric Microbiome Metabolites Correlate with Response to Simvastatin TreatmentPLOS ONE, 2011
- The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive reviewRheumatology International, 2011
- Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome CohortPLOS ONE, 2011
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive ProteinCirculation: Cardiovascular Quality and Outcomes, 2009
- A gift from nature: the birth of the statinsNature Medicine, 2008
- Variations and increase in use of statins across Europe: data from administrative databasesBMJ, 2004